Dr. Philip A. Philip, MD, PhD

Dr. Philip practices at Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Philip's NPI, 1316985484, was assigned on June 2, 2006. Dr. Philip holds Michigan license 4301066240.

Dr. Philip's primary practice is Henry Ford Hospital, at 2799 W Grand Blvd, Detroit, MI 48202 in Wayne County. The practice phone is (313) 916-2600.

Dr. Philip's primary practice is Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Philip is also affiliated with Karmanos Cancer Center. The medical group on file is Henry Ford Health. Dmand AI also links Dr. Philip to 4 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Philip practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Philip's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Philip is licensed in Michigan.

CMS data shows 181 Medicare services from Dr. Philip across 4 procedure codes in 2024, for 105 Medicare patients. Medicare paid $16,619 for them.

CMS counts 105 Medicare patients who saw Dr. Philip in 2024. The largest group is 65 to 74, with 51 patients. 72% of them have high blood pressure, and 68% have high cholesterol. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Philip's median patient age at 68, with 64% women.

In 2024, Dr. Philip wrote 65 Medicare Part D claims for 33 patients. 66% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $7,646 in total drug cost. In 2021, CMS named 51 claims across 2 drugs.

Dr. Philip accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Philip as offering telehealth.

Dmand AI links 26 papers to Dr. Philip, published from 2010 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms and Adenocarcinoma. Dr. Philip has published most often in Microb Cell Fact. Dr. Philip's most frequent co-authors are Syed Arif Ahmad, MD, Jeffrey A. Meyerhardt, MD, MPH and Tareq Al Baghdadi, MD.

Dmand AI links Dr. Philip to 12 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Biliary Tract Neoplasms, Esophageal Squamous Cell Carcinoma and Headache. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Philip that name 3 trials.

CMS Open Payments shows 658 general payments to Dr. Philip from 43 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 45% of the total. Celgene Corporation paid the most, $134,771. It also lists 10 research payments totaling $52,448 from 2016 to 2019, naming 3 clinical trials.